The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.

Leo ThomasEric MartelWolfgang RistIngo UphuesDieter HamprechtHeike NeubauerRobert Augustin

Published in: Diabetes, obesity & metabolism (2024)

Survodutide was selected as the clinical candidate based on its balanced dual GCGR/GLP-1R pharmacology, engaging the GCGR for robust body weight-lowering efficacy exceeding that of selective GLP-1R agonists, while achieving antidiabetic efficacy that was comparable to selective GLP-1R agonism. Survodutide is currently being investigated in Phase 3 clinical trials in people living with obesity.

Keyphrases

body weight
clinical trial
metabolic syndrome
type diabetes
insulin resistance
weight gain
adipose tissue
body mass index
physical activity
high resolution